Animal Models of Disease, Part C, Volume 192 in the Methods in Cell Biology series, highlights advances in the field, with this new volume presenting interesting chapters on a variety of timely topics, including Using C. Elegans as a model for Neurodegenerative disease: Methodology and Evaluation, Modelo Animal de Esclerosis Multiple: Encefalomielitis Autoimmune Experimental (EAE, New mouse model to study aneurysm development, Spinal Nerve Ligation: An Experimental Neuropathic Pain Model in Rats and Mice, Identifying therapeutic compounds for Autosomal Dominant Optic Atrophy (ADOA) through screening in the nematode C. elegans, Eµ-TCL1 adoptive transfer mouse model of chronic lymphocytic leukemia, and much more. Other chapters cover Purification and characterization of kidney-infiltrating leukocytes in a mouse model of lupus nephritis, Differences in intratumor innate lymphoid cell composition between orthotopic and spontaneous pancreatic mouse models, Assessing motor development and function in mouse models of neurodevelopmental disorders, Analysis of Gut Microbiota profile targeted to multi hypervariable regions of 16S rRNA in hypertensive heart failure rat model, and more.
See more
Current price
€145.34
Original price
€152.99
Save 5%
Will deliver when available. Publication date 01 Feb 2025
Product Details
Dimensions: 152 x 229mm
Publication Date: 01 Feb 2025
Publisher: Elsevier Science Publishing Co Inc
Publication City/Country: United States
Language: English
ISBN13: 9780443222429
About
Lorenzo Galluzzi is Assistant Professor of Cell Biology in Radiation Oncology at the Department of Radiation Oncology of the Weill Cornell Medical College Honorary Assistant Professor Adjunct with the Department of Dermatology of the Yale School of Medicine Honorary Associate Professor with the Faculty of Medicine of the University of Paris and Faculty Member with the Graduate School of Biomedical Sciences and Biotechnology of the University of Ferrara the Graduate School of Pharmacological Sciences of the University of Padova and the Graduate School of Network Oncology and Precision Medicine of the University of Rome La Sapienza”. Moreover he is Associate Director of the European Academy for Tumor Immunology and Founding Member of the European Research Institute for Integrated Cellular Pathology. Galluzzi is best known for major experimental and conceptual contributions to the fields of cell death autophagy tumor metabolism and tumor immunology. He has published over 450 articles in international peer-reviewed journals and is the Editor-in-Chief of four journals: OncoImmunology (which he co-founded in 2011) International Review of Cell and Molecular Biology Methods in Cell biology and Molecular and Cellular Oncology (which he co-founded in 2013). Additionally he serves as Founding Editor for Microbial Cell and Cell Stress and Associate Editor for Cell Death and Disease Pharmacological Research and iScience. Fernando Aranda holds a BSc in Biology (2006) and Biochemistry (2007) from the University of Navarra. Then he specialized in different strategies of Cancer Immunotherapy with a MSc in Biomedical Research (2008) and a PhD Degree (2012) from the University of Navarra (Pamplona) Cima University of Navarra. More than 12 years in translational research focus on antitumor immune responses and Cancer Immunotherapy. Author of 64 publications indexed in PubMed in prestigious international journals with h-index 30 and 4296 cites (October 2022). He completed the Program of Sara Borrell (ISCIII) -competitive Postdoctoral contract- in the Group of Immune Receptors of the Innate and Adaptive System (IDIBAPS) Barcelona (2016-2018). Co-author of 1 invention patent: Composition based on the fibronectin domain A for the treatment of melanoma - WO/2011/101332. In 2012 Fernando Aranda obtained a Scientific Award Profesor Durantez II Edición for the best scientific article in Tumor Immunology by Fundación LAIR. Recently Fernando Aranda awarded a competitive Research Fellow contract Miguel Servet tipo I” by Instituto de Salud Carlos III to continue his independent researcher career (IP) in cancer immunotherapy issues. Specifically he is involved in Translational Immunotherapy of Peritoneal Carcinomatosis. Currently Fernando Aranda leads a research group in cooperation with Dr. Pedro Berraondo. Aitziber Buqué is currently a Post-Doctoral Associate with the Galluzzi Lab in the Department of Radiation Oncology at Weill Cornell Medical College (New York) where she investigates innate and acquired mechanisms of resistance to immunotherapy in HR+ breast cancer and radiotherapy as a means to overcome them. Prior to joining the Galluzzi Lab (2018) Aitziber was a Post-Doctoral Associate with the Kroemer Lab in the Cordeliers Research Center (Paris France; 2014-2018) after receiving her M.Sc. in Bioinformatics and Computational Biology (2006) from the Complutense University (Madrid Spain) and her Ph.D. in Biomedicine (2013) from the BioCruces Research Institute (Barakaldo Spain). Aitziber has a long-standing interest in the immunological mechanisms controlling cancer progression and response to treatment. Jose Manuel Bravo-San Pedro is currently a researcher at the Department of Physiology of the Complutense University of Madrid thanks to a Ramon y Cajal contract grant. He got his Ph.D. in biochemistry cellular biology and genetics from the University of Extremadura (Caceres Spain) in 2011 and he did a post-doctoral stage in the laboratory of Prof. Guido Kroemer. His main research interests have always been linked to autophagy addressing this cellular process associated with neurodegenerative diseases or cancer and recently obesity and specifically related to problems in the correct functioning of the cilium. He is co-inventor of two patents and co-author of 110 publications indexed in PubMed in prestigious international journals with h-index 45 and 23768 cites (Dec 2022).